Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix Full Year Results 2025 Investor Webcast Notification
- First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
- Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
- Telix Achieves FY25 Guidance - US$804M, Q4 Growth
- Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Later from Telix Pharmaceuticals
- 2025 Full Year Results Announcement
- Appendix 4E and 2025 Annual Report
- 2025 Full Year Results Presentation
- FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
- Telix to Participate in Oppenheimer and TD Cowen Conferences
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals